30 results on '"Bernit, E."'
Search Results
2. P-019: ENDOTHELIAL ACTIVATION BIOMARKERS FOR THE RISK OF CHRONIC MICROVASCULAR COMPLICATIONS IN SICKLE CELL DISEASE
- Author
-
AGOUTI I., MASSON E., JEAN-MIGNARD E., ARNAUD L., ABDILI E., BERENGER P., LAVOIPIERRE V., LACROIX R., and BERNIT E.
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2022
- Full Text
- View/download PDF
3. P-041: DEATH ASSOCIATED WITH DELTA VARIANT COVID-19 AMONG SICKLE CELL DISEASE ADULT PATIENTS DURING THE 2021 4TH WAVE IN GUADELOUPE
- Author
-
BERNIT E., TARER V., HARDY-DESSOURCES M., TRESSIÈRES B., DOUMDO L., PETRAS E., ROMANA M., and ETIENNE-JULAN M.
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2022
- Full Text
- View/download PDF
4. P-025: ABNORMAL MITOCHONDRIA RETENTION IN MATURE RED BLOOD CELLS OCCURS NOT ONLY IN SS BUT ALSO SC PATIENTS AND IS ASSOCIATED WITH HEMOLYTIC MARKERS
- Author
-
ROMANA M., HARDY-DESSOURCES M., RAVION S., GARNIER Y., REININGER L., TARER V., TRESSIÈRE B., BERNIT E., LE VAN KIM C., BACCINI V., and ETIENNE-JULAN M.
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2022
- Full Text
- View/download PDF
5. In vitro microparticle-dependent clot formation mainly depends on platelet-derived microparticles and not on other subtypes: PB 3.30–6
- Author
-
Bouriche, T, Judicone, C, Lacroix, R, Bernit, E, Harti, K, Albanese, J, Dignat-George, F, and Poncelet, Ph
- Published
- 2013
6. Rituximab as Preventive Therapy of a Clinical Relapse in TTP With ADAMTS13 Inhibitor
- Author
-
Schleinitz, N., Ebbo, M., Mazodier, K., Poullin, P., Bernit, E., Veit, V., Veyradier, A., Fakhouri, F., Kaplanski, G., and Harle, J. R.
- Published
- 2007
- Full Text
- View/download PDF
7. Monoclonal antibody immunospecific platelet assay in patients with lupus anticoagulant and prolonged bleeding time: Comment on the article by Urbanus et al
- Author
-
Schleinitz, N., Camoin, L., Bernit, E., Reviron, D., Veit, V., and Harlé, J. R.
- Published
- 2005
8. PF788 DATA FROM THE FRENCH REGISTRY FOR BETA-THALASSEMIA PATIENTS
- Author
-
Agouti, I., primary, Thuret, I., additional, Bernit, E., additional, Galacteros, F., additional, Steschenko, D., additional, Brousse, V., additional, Rose, C., additional, HOT, A., additional, Ribeil, J.-A., additional, Pegourie, B., additional, Lambilliotte, A., additional, Lionnet, F., additional, Auguste, Y., additional, Loundou, A., additional, and Badens, C., additional
- Published
- 2019
- Full Text
- View/download PDF
9. Contribution of Systematic Serological Testing in Diagnosis of Infective Endocarditis
- Author
-
Raoult, D., primary, Casalta, J. P., additional, Richet, H., additional, Khan, M., additional, Bernit, E., additional, Rovery, C., additional, Branger, S., additional, Gouriet, F., additional, Imbert, G., additional, Bothello, E., additional, Collart, F., additional, and Habib, G., additional
- Published
- 2005
- Full Text
- View/download PDF
10. High risk of progression for chronic major organ complications of sickle cell disease in adolescents and young adults: A long-term neonatal cohort study.
- Author
-
Borgey M, Genty I, Habibi A, Arlet JB, Dhedin N, Lionnet F, Bernit E, Julan ME, Loko G, Arnaud C, Kamdem A, Pissard S, Guémas E, Noizat C, and Pondarré C
- Subjects
- Humans, Adolescent, Male, Female, Young Adult, Infant, Newborn, Adult, Cohort Studies, Risk Factors, Chronic Disease, Anemia, Sickle Cell complications, Disease Progression
- Published
- 2024
- Full Text
- View/download PDF
11. A study of 28 pregnant women with sickle cell disease and COVID-19: elevated maternal and fetal morbidity rates.
- Author
-
Joseph L, De Luna G, Bernit E, Cougoul P, Santin A, Faucher B, Habibi A, Garou A, Loko G, Mattioni S, Manceau S, Arlet JB, and Lionnet F
- Subjects
- Humans, Female, Pregnancy, Adult, Pregnancy Complications, Hematologic epidemiology, Young Adult, Infant, Newborn, COVID-19 complications, COVID-19 epidemiology, Anemia, Sickle Cell complications, Anemia, Sickle Cell epidemiology, Anemia, Sickle Cell therapy, SARS-CoV-2, Pregnancy Complications, Infectious virology
- Published
- 2024
- Full Text
- View/download PDF
12. Pain Control for Sickle Cell Crisis, a Novel Approach? A Retrospective Study.
- Author
-
Rollé A, Vidal E, Laguette P, Garnier Y, Delta D, Martino F, Portecop P, Etienne-Julan M, Piednoir P, De Jong A, Romana M, and Bernit E
- Subjects
- Adult, Female, Humans, Pain Management methods, Retrospective Studies, Analgesics, Opioid therapeutic use, Pain drug therapy, Pain etiology, Analgesics therapeutic use, Volatile Organic Compounds, Anemia, Sickle Cell complications
- Abstract
Background and Objectives : Pain management poses a significant challenge for patients experiencing vaso-occlusive crisis (VOC) in sickle cell disease (SCD). While opioid therapy is highly effective, its efficacy can be impeded by undesirable side effects. Local regional anesthesia (LRA), involving the deposition of a perineural anesthetic, provides a nociceptive blockade, local vasodilation and reduces the inflammatory response. However, the effectiveness of this therapeutic approach for VOC in SCD patients has been rarely reported up to now. The objective of this study was to assess the effectiveness of a single-shot local regional anesthesia (LRA) in reducing pain and consequently enhancing the management of severe vaso-occlusive crisis (VOC) in adults with sickle cell disease (SCD) unresponsive to conventional analgesic therapy. Materials and Methods : We first collected consecutive episodes of VOC in critical care (ICU and emergency room) for six months in 2022 in a French University hospital with a large population of sickle cell patients in the West Indies population. We also performed a systematic review of the use of LRA in SCD. The primary outcome was defined using a numeric pain score (NPS) and/or percentage of change in opioid use. Results : We enrolled nine SCD adults (28 years old, 4 females) for ten episodes of VOC in whom LRA was used for pain management. Opioid reduction within the first 24 h post block was -75% (50 to 96%). Similarly, the NPS decreased from 9/10 pre-block to 0-1/10 post-block. Five studies, including one case series with three patients and four case reports, employed peripheral nerve blocks for regional anesthesia. In general, local regional anesthesia (LRA) exhibited a reduction in pain and symptoms, along with a decrease in opioid consumption post-procedure. Conclusions : LRA improves pain scores, reduces opioid consumption in SCD patients with refractory pain, and may mitigate opioid-related side effects while facilitating the transition to oral analgesics. Furthermore, LRA is a safe and effective procedure.
- Published
- 2023
- Full Text
- View/download PDF
13. HLA-F and LILRB1 Genetic Polymorphisms Associated with Alloimmunisation in Sickle Cell Disease.
- Author
-
Bernit E, Jean E, Marlot B, Laget L, Izard C, Dettori I, Beley S, Gautier I, Agouti I, Frassati C, Pedini P, Picard C, Paganini J, Chiaroni J, and Di Cristofaro J
- Subjects
- Adult, Female, Pregnancy, Humans, Leukocyte Immunoglobulin-like Receptor B1, Ligands, Genes, MHC Class I, Antigens, CD, Anemia, Sickle Cell genetics, Anemia, Sickle Cell therapy, Anemia, Hemolytic, Autoimmune
- Abstract
Red blood cell (RBC) transfusion remains a critical component in caring for the acute and chronic complications of sickle cell disease (SCD). Patient alloimmunisation is the main limitation of transfusion, which can worsen anaemia and lead to delayed haemolytic transfusion reaction or transfusion deadlock. Although biological risk factors have been identified for immunisation, patient alloimmunisation remains difficult to predict. We aimed to characterise genetic alloimmunisation factors to optimise the management of blood products compatible with extended antigen matching to ensure the self-sufficiency of labile blood products. Considering alloimmunisation in other clinical settings, like pregnancy and transplantation, many studies have shown that HLA Ib molecules (HLA-G, -E, and -F) are involved in tolerance mechanism; these molecules are ligands of immune effector cell receptors (LILRB1, LILRB2, and KIR3DS1). Genetic polymorphisms of these ligands and receptors have been linked to their expression levels and their influence on inflammatory and immune response modulation. Our hypothesis was that polymorphisms of HLA Ib genes and of their receptors are associated with alloimmunisation susceptibility in SCD patients. The alloimmunisation profile of thirty-seven adult SCD patients was analysed according to these genetic polymorphisms and transfusion history. Our results suggest that the alloimmunisation of SCD patients is linked to both HLA-F and LILRB1 genetic polymorphisms located in their regulatory region and associated with their protein expression level.
- Published
- 2023
- Full Text
- View/download PDF
14. Outcomes of Pregnancy in Sickle Cell Disease Patients: Results from the Prospective ESCORT-HU Cohort Study.
- Author
-
Habibi A, Cannas G, Bartolucci P, Voskaridou E, Joseph L, Bernit E, Gellen-Dautremer J, Charneau C, Ngo S, and Galactéros F
- Abstract
Sickle cell disease (SCD) refers to a group of inherited hemoglobin disorders in which sickle red blood cells display altered deformability, leading to a significant burden of acute and chronic complications, such as vaso-occlusive pain crises (VOCs). Hydroxyurea is a major therapeutic agent in adult and pediatric sickle cell patients. This treatment is an alternative to transfusion in some complications. Indeed, it increases hemoglobin F and has an action on the endothelial adhesion of red blood cells, leukocytes, and platelets. Although the safety profile of hydroxyurea (HU) in patients with sickle cell disease has been well established, the existing literature on HU exposure during pregnancy is limited and incomplete. Pregnancy in women with SCD has been identified as a high risk for the mother and fetus due to the increased incidence of maternal and non-fetal complications in various studies and reports. For women on hydroxyurea at the time of pregnancy, transfusion therapy should probably be initiated after pregnancy. In addition, there is still a significant lack of knowledge about the incidence of pregnancy, fetal and maternal outcomes, and management of pregnant women with SCD, making it difficult to advise women or clinicians on outcomes and best practices. Therefore, the objective of this study was to describe pregnancy outcomes ( n = 128) reported in the noninterventional European Sickle Cell Disease COhoRT-HydroxyUrea (ES-CORT-HU) study. We believe that our results are important and relevant enough to be shared with the scientific community.
- Published
- 2023
- Full Text
- View/download PDF
15. Case Report of Myelodysplastic Syndrome in a Sickle-Cell Disease Patient Treated with Hydroxyurea and Literature Review.
- Author
-
Flevari P, Voskaridou E, Galactéros F, Cannas G, Loko G, Joseph L, Bartolucci P, Gellen-Dautremer J, Bernit E, Charneau C, and Habibi A
- Abstract
The safety profile of hydroxyurea (HU) in patients with sickle-cell disease (SCD) is relatively well known. However, despite the suspected association of HU with myeloid neoplasms in myeloproliferative neoplasms (MPN), and the publication of sporadic reports of myeloid malignancies in SCD patients treated with HU, the possible excess risk imparted by HU in this population having an increasing life expectancy has failed to be demonstrated. Herein, we report one case of myelodysplastic syndrome emanating from the results on safety and effectiveness of HU on the largest European cohort of 1903 HU-treated adults and children who were followed-up prospectively in an observational setting over 10 years, accounting for a total exposure of 7309.5 patient-years. A comparison of this single case with previously published similar cases did not allow us to draw any significant conclusions due to the paucity of these events.
- Published
- 2022
- Full Text
- View/download PDF
16. Sickle cell disease patients with COVID-19 in Guadeloupe: Surprisingly favorable outcomes.
- Author
-
Bernit E, Romana M, Alexis-Fardini S, Tarer V, Roger PM, Doumdo L, Petras E, Charneau C, Tressières B, Dessources MDH, and Etienne-Julan M
- Abstract
We investigate risk factors for hospitalization and difference between sickle cell syndromes in a cohort of COVID-19 sickle cell disease (SCD) adult patients managed in the Reference Center of Guadeloupe. We retrospectively collected data of symptomatic SCD adult patients infected with SARS-CoV-2 between March and December 2020. Thirty-eight SCD adult patients with symptomatic COVID-19 infection were included during the first wave, representing 9.6% of the active patient file at our center. The median age (IQR) was 39 years (24-47). Four patients were obese and two had moderate renal failure. The median duration of symptoms (IQR) was 10 days (5-15). Seventeen (44.7%) patients were hospitalized, including two in intensive care unit (ICU) for acute chest syndrome. An 85-year-old SC patient with prostate cancer died. No difference was detected between inpatient and outpatient groups in terms of age, gender, BMI, SCD clinical complications, and in history SCD treatment. There was no difference for severity, hospitalization, length of stay, ICU stay, or death between SS or Sβ°-thal patients and SC or Sβ
+ -thal patients. These overall favorable outcomes among symptomatic patients may be related to the low prevalence of comorbidity known to be linked to the more severe forms of COVID-19, but also to the prompt coordinated management of SCD patients in the Reference Center., Competing Interests: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported., (© 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.)- Published
- 2022
- Full Text
- View/download PDF
17. Unusual calcium pyrophosphate deposition disease.
- Author
-
Muller R, Bernit E, Ebbo M, and Schleinitz N
- Subjects
- Humans, Middle Aged, Calcium Pyrophosphate metabolism, Chondrocalcinosis diagnostic imaging, Spinal Diseases diagnostic imaging
- Published
- 2022
- Full Text
- View/download PDF
18. Risk factors for severe COVID-19 in hospitalized sickle cell disease patients: A study of 319 patients in France.
- Author
-
Arlet JB, Lionnet F, Khimoud D, Joseph L, de Montalembert M, Morisset S, Garou A, Cannas G, Cougoul P, Guitton C, Holvoet L, Odièvre MH, Cheminet G, Bartolucci P, Santin A, Bernit E, and de Luna G
- Subjects
- Adolescent, Adult, COVID-19 diagnosis, Female, France epidemiology, Hospitalization, Humans, Male, Risk Factors, SARS-CoV-2 isolation & purification, Severity of Illness Index, Young Adult, Anemia, Sickle Cell complications, COVID-19 etiology
- Published
- 2022
- Full Text
- View/download PDF
19. In vivo muscle function and energetics in women with sickle cell anemia or trait: a 31 P-magnetic resonance spectroscopy study.
- Author
-
Chatel B, Bernit E, Vilmen C, Michel C, Bendahan D, and Messonnier LA
- Subjects
- Humans, Magnetic Resonance Spectroscopy, Muscle, Skeletal, Phosphocreatine, Anemia, Sickle Cell, Sickle Cell Trait
- Abstract
Sickle cell anemia (SCA) is a genetic hemoglobinopathy associated with an impaired oxygen delivery to skeletal muscle that could alter ATP production processes and increase intramuscular acidosis. These alterations have been already reported in the Townes mouse model of SCA but the corresponding changes in humans have not been documented. In the present study, we used 31-phosphorus magnetic resonance spectroscopy to investigate in vivo the metabolic changes induced by a moderate-intensity exercise in twelve SCA patients, eight sickle cell trait (SCT) carriers, and twelve controls women. The rest-exercise-recovery protocol disclosed slight differences regarding phosphocreatine (PCr) consumption and lactate accumulation between SCA patients and controls but these differences did not reach a statistical significance. On that basis, the in vivo metabolic changes associated with a moderate-intensity muscle exercise were slightly altered in SCA patients and SCT carriers but within a normal range. The present results strongly support the fact that a moderate-intensity exercise is safe and could be recommended in stable SCA patients and SCT subjects. NEW & NOTEWORTHY The main finding of the present study was that the metabolic changes associated with a moderate-intensity muscle exercise were slightly modified in stable sickle cell anemia patients and sickle cell trait carriers as compared to controls but still in the normal range. The present results strongly support the safety of a moderate-intensity exercise for stable sickle cell anemia patients and sickle cell trait carriers.
- Published
- 2021
- Full Text
- View/download PDF
20. T Cell Polarization toward T H 2/T FH 2 and T H 17/T FH 17 in Patients with IgG4-Related Disease.
- Author
-
Grados A, Ebbo M, Piperoglou C, Groh M, Regent A, Samson M, Terrier B, Loundou A, Morel N, Audia S, Maurier F, Graveleau J, Hamidou M, Forestier A, Palat S, Bernit E, Bonotte B, Farnarier C, Harlé JR, Costedoat-Chalumeau N, Vély F, and Schleinitz N
- Abstract
IgG4-related disease (IgG4-RD) is a fibro-inflammatory disorder involving virtually every organ with a risk of organ dysfunction. Despite recent studies regarding B cell and T cell compartments, the disease's pathophysiology remains poorly understood. We examined and characterized subsets of circulating lymphocytes in untreated patients with active IgG4-RD. Twenty-eight consecutive patients with biopsy-proven IgG4-RD were included in a prospective, multicentric study. Lymphocytes' subsets were analyzed by flow cytometry, with analysis of T
H 1/TH 2/TH 17, TFH cells, and cytokine release by peripheral blood mononuclear cells. Results were compared to healthy controls and to patients with primary Sjögren's syndrome. Patients with IgG4-RD showed an increase of circulating T regulatory, TH 2, TH 17, and CD4+ CXCR5+ PD1+ TFH cell subsets. Accordingly, increased levels of IL-10 and IL-4 were measured in IgG-RD patients. TFH increase was characterized by the specific expansion of TFH 2 (CCR6- CXCR3- ), and to a lesser extent of TFH 17 (CCR6+ CXCR3- ) cells. Interestingly, CD4+ CXCR5+ PD1+ TFH cells normalized under treatment. IgG4-RD is characterized by a shift of circulating T cells toward a TH 2/TFH 2 and TH 17/TFH 17 polarization. This immunological imbalance might be implicated in the disease's pathophysiology. Treatment regimens targeting such T cells warrant further evaluation.- Published
- 2017
- Full Text
- View/download PDF
21. Ophthalmic manifestations in IgG4-related disease: Clinical presentation and response to treatment in a French case-series.
- Author
-
Ebbo M, Patient M, Grados A, Groh M, Desblaches J, Hachulla E, Saadoun D, Audia S, Rigolet A, Terrier B, Perlat A, Guillaud C, Renou F, Bernit E, Costedoat-Chalumeau N, Harlé JR, and Schleinitz N
- Subjects
- Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents therapeutic use, Eye Diseases drug therapy, Eye Diseases pathology, Female, Humans, Male, Middle Aged, Prednisone therapeutic use, Retrospective Studies, Young Adult, Eye pathology, Eye Diseases immunology, Immune System Diseases complications, Immunoglobulin G
- Abstract
IgG4-related disease (IgG4-RD) is characterized by variable tissue or organ involvements sharing common pathological findings. Orbital or orbital adnexa involvement of the disease has been reported in a few case series. The aim of our study was to characterize and analyze ophthalmic manifestations from a nationwide French case-series.Patients with IgG4-RD and orbital or orbital adnexa involvement included in the French multicentric IgG4-RD case-registry were identified. Only patients fulfilling "modified" comprehensive diagnostic criteria with pathological documentation were retained for the study. Clinical, biological, pathological, radiological findings and data regarding the response to treatment were retrospectively analyzed.According to our data registry, the frequency of IgG4-related ophthalmic disease (IgG4-ROD) was 17%. Mean age at diagnosis was 55.1 ± 7.1 years with a male/female ratio of 2.2. The 19 cases of IgG4-ROD consisted of lacrimal gland (68.4%), soft tissue (57.9%), extra-ocular muscles (36.8%), palpebral (21.1%), optical nerve (10.5%), orbital bone (10.5%), and mononeuritis (V1 and/or V2, 10.5%) involvements. IgG4-ROD was bilateral in 57.9% of cases. Extra-ophthalmic manifestations were reported in 78.9% of cases. All patients responded to prednisone but two-thirds of patients relapsed within a mean (SD) of 9.8 (3.5) months and 72.2% required long-term glucocorticoids and/or immunosuppressive agents. Eight patients were treated by rituximab with a favorable response in 87.5% of cases.Lacrimal involvement is the most frequent ophthalmic manifestation of IgG4-RD and is frequently associated with extra-orbital manifestations. Despite initial favorable response to steroids, the long-term management of relapsing patients needs to be improved.
- Published
- 2017
- Full Text
- View/download PDF
22. Esophageal and anorectal involvement in systemic sclerosis: a systematic assessment with high resolution manometry.
- Author
-
Luciano L, Granel B, Bernit E, Harle JR, Baumstarck K, Grimaud JC, Bouvier M, and Vitton V
- Subjects
- Aged, Anal Canal diagnostic imaging, Constipation etiology, Constipation physiopathology, Constipation psychology, Defecation, Deglutition, Deglutition Disorders etiology, Deglutition Disorders physiopathology, Deglutition Disorders psychology, Endosonography, Fecal Incontinence etiology, Fecal Incontinence physiopathology, Fecal Incontinence psychology, Female, France, Gastroesophageal Reflux etiology, Gastroesophageal Reflux physiopathology, Gastroesophageal Reflux psychology, Gastrointestinal Motility, Humans, Male, Middle Aged, Predictive Value of Tests, Pressure, Quality of Life, Rectum diagnostic imaging, Retrospective Studies, Risk Factors, Scleroderma, Systemic diagnosis, Scleroderma, Systemic physiopathology, Scleroderma, Systemic psychology, Severity of Illness Index, Surveys and Questionnaires, Anal Canal physiopathology, Constipation diagnosis, Deglutition Disorders diagnosis, Esophagus physiopathology, Fecal Incontinence diagnosis, Gastroesophageal Reflux diagnosis, Manometry methods, Rectum physiopathology, Scleroderma, Systemic complications
- Abstract
Objectives: In systemic sclerosis (SSc), esophageal and anorectal involvements are frequent and often associated with each other. In clinical practice, esophageal explorations are often prescribed, while anorectal explorations are rarely proposed and therefore, under-recognised. However, it is well documented in the literature that early detection of anorectal dysfunction could delay and/or prevent the onset of symptoms such as fecal incontinence (FI). The main objective was the systematic evaluation and detection of esophageal and anorectal involvements in SSc patients., Methods: In this monocentric retrospective study, all patients with SSc addressed in the Department of Functional Digestive Explorations, North Hospital, Marseille for esophageal and anorectal explorations were included. Self-Questionnaires, evaluating the symptoms and quality of life, were filled by patients during their visit. Explorations were performed on the same day: high resolution esophageal manometry (EHRM), 3 Dimensional high resolution anorectal manometry (3DHRARM) and endo anal sonography (EUS)., Results: 44 patients (41 women), mean age 59.8±12 years, were included. With regard to the symptoms, 45.5% of patients had gastro-esophageal reflux disease (GERD), 66.9% dysphagia, 65.9% constipation and 77.3% FI. The incidence of esophageal dismotility was 65.9%, anorectal and both upper and lower dysfunction were 43.2%. More than 89% patients with abnormal explorations (EHRM, 3DHRARM or both) were symptomatic. Duration of SSc and altered quality of life was correlated with the severity of digestive involvement., Conclusions: Anorectal dysfunction appears to be closely linked to esophageal involvement in SSc. Their routine screening is undoubtedly essential to limit the occurrence of severe symptoms such as FI.
- Published
- 2016
23. Emerging role of Raoultella ornithinolytica in human infections: a series of cases and review of the literature.
- Author
-
Seng P, Boushab BM, Romain F, Gouriet F, Bruder N, Martin C, Paganelli F, Bernit E, Le Treut YP, Thomas P, Papazian L, Raoult D, and Stein A
- Subjects
- Anti-Bacterial Agents therapeutic use, Bacteremia microbiology, Cross Infection microbiology, Drug Resistance, Bacterial, Enterobacteriaceae drug effects, Female, Humans, Male, Retrospective Studies, Enterobacteriaceae isolation & purification, Enterobacteriaceae Infections microbiology
- Abstract
Background: Raoultella ornithinolytica is known to inhabit aquatic environments. The clinical features and outcomes of human infections caused by R. ornithinolytica have been reported for only a limited number of cases., Methods: A retrospective study of cases of infection caused by R. ornithinolytica managed at four university hospital centres during the period before and after the introduction of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) was performed. The aim was to describe the clinical and microbiological characteristics, treatments, and outcomes., Results: Among 187 R. ornithinolytica isolates identified for which clinical information was available, 71 were considered colonizers and 116 were pathogenic. A total of 112 cases of R. ornithinolytica infection were identified. Urinary tract infections, gastrointestinal infections, wound and skin infections, and bacteraemia were observed in 36%, 14%, 13%, and 5% of cases, respectively. Associated infections that have been poorly reported, such as respiratory infections, i.e. pneumonia and pleural effusion, were observed in 24% of cases. Additional diseases reported here for the first time included osteomyelitis, meningitis, cerebral abscess, mediastinitis, pericarditis, conjunctivitis, and otitis. The proportion of R. ornithinolytica isolates resistant to antibiotics was found to be relatively high: 4% of isolates were resistant to ceftriaxone, 6% to quinolones, and 13% to co-trimoxazole. The mortality rate related to infection was 5%., Conclusions: R. ornithinolytica is an underreported, emerging hospital-acquired infection and is particularly associated with invasive procedures. R. ornithinolytica should never be considered simply a saprophytic bacterium that occasionally contaminates bronchial lavage or other deep respiratory samples or surgical sites. Physicians should be aware of the high rates of antimicrobial resistance of R. ornithinolytica isolates so that immediate broad-spectrum antibiotic treatment can be established before accurate microbiological results are obtained., (Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
24. Sarcoidosis Occurring After Solid Cancer: A Nonfortuitous Association: Report of 12 Cases and Review of the Literature.
- Author
-
Grados A, Ebbo M, Bernit E, Veit V, Mazodier K, Jean R, Coso D, Aurran-Schleinitz T, Broussais F, Bouabdallah R, Gravis G, Goncalves A, Giovaninni M, Sève P, Chetaille B, Gavet-Bongo F, Weitten T, Pavic M, Harlé JR, and Schleinitz N
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Retrospective Studies, Neoplasms complications, Sarcoidosis etiology
- Abstract
The association between cancer and sarcoidosis is controversial. Some epidemiological studies show an increase of the incidence of cancer in patients with sarcoidosis but only few cases of sarcoidosis following cancer treatment have been reported. We conducted a retrospective case study from internal medicine and oncology departments for patients presenting sarcoidosis after solid cancer treatment. We also performed a literature review to search for patients who developed sarcoidosis after solid cancer. We describe the clinical, biological, and radiological characteristics and outcome of these patients. Twelve patients were included in our study. Various cancers were observed with a predominance of breast cancer. Development of sarcoidosis appeared in the 3 years following cancer and was asymptomatic in half of the patients. The disease was frequently identified after a follow-up positron emission tomography computerized tomography evaluation. Various manifestations were observed but all patients presented lymph node involvement. Half of the patients required systemic therapy. With a median follow-up of 73 months, no patient developed cancer relapse. Review of the literature identified 61 other patients for which the characteristics of both solid cancer and sarcoidosis were similar to those observed in our series. This report demonstrates that sarcoidosis must be considered in the differential diagnosis of patients with a history of malignancy who have developed lymphadenopathy or other lesions on positron emission tomography computerized tomography. Histological confirmation of cancer relapse is mandatory in order to avoid unjustified treatments. This association should be consider as a protective factor against cancer relapse.
- Published
- 2015
- Full Text
- View/download PDF
25. A new family with hereditary lysozyme amyloidosis with gastritis and inflammatory bowel disease as prevailing symptoms.
- Author
-
Jean E, Ebbo M, Valleix S, Benarous L, Heyries L, Grados A, Bernit E, Grateau G, Papo T, Granel B, Daniel L, Harlé JR, and Schleinitz N
- Subjects
- Adult, Aged, Amyloidosis, Familial pathology, Amyloidosis, Familial physiopathology, Female, Gastritis pathology, Gastritis physiopathology, Humans, Inflammatory Bowel Diseases pathology, Inflammatory Bowel Diseases physiopathology, Male, Middle Aged, Mutation, Pedigree, Phenotype, Young Adult, Amyloidosis, Familial genetics, Gastritis genetics, Inflammatory Bowel Diseases genetics, Muramidase genetics
- Abstract
Background: Systemic amyloidoses is a heterogeneous group of diseases either acquired or hereditary. Amyloidoses can involve the gastrointestinal tract and the nature of the precursor protein that forms the fibrils deposits should be identified to adjust the treatment and evaluate the prognosis. Lysozyme amyloidosis (ALys) is a rare, systemic non neuropathic hereditary amyloidosis with a heterogenous phenotype including gastrointestinal, renal and hepatic symptoms., Case Presentation: We report and describe symptoms and gastrointestinal tract involvement in a new family with hereditary lysozyme amyloidosis. Clinical manifestations and organ involvement of nine affected members of a new family with the p.Trp82Arg ALys variant were recorded. All affected individuals suffered with prevailing gastrointestinal symptoms leading to the diagnosis of ALys. 8/9 had non specific upper gastrointestinal symptoms and 3/9 had rectocolic inflammation evoking inflammatory bowel disease. No other organ involvement by amyloidosis was found. Histological examination revealed amyloid deposits in all cases and all carried the p.Trp82Arg ALys variant at a heterozygous state., Conclusion: Hereditary amyloidosis associated with the p.Trp82Arg lysozyme variant in this new family is predominantly associated with mild upper gastrointestinal tract involvement and in some cases with inflammatory bowel disease. Amyloidosis should be considered in atypical or treatment resistant, upper or lower chronic gastrointestinal symptoms. When associated with a familial history a lysozyme gene mutation must be searched.
- Published
- 2014
- Full Text
- View/download PDF
26. Usefulness of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography for staging and evaluation of treatment response in IgG4-related disease: a retrospective multicenter study.
- Author
-
Ebbo M, Grados A, Guedj E, Gobert D, Colavolpe C, Zaidan M, Masseau A, Bernard F, Berthelot JM, Morel N, Lifermann F, Palat S, Haroche J, Mariette X, Godeau B, Bernit E, Costedoat-Chalumeau N, Papo T, Hamidou M, Harlé JR, and Schleinitz N
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Murine-Derived therapeutic use, Female, Fluorodeoxyglucose F18 metabolism, Humans, Immunosuppressive Agents therapeutic use, Male, Middle Aged, Multiple Organ Failure metabolism, Prednisone therapeutic use, Retrospective Studies, Rituximab, Sensitivity and Specificity, Steroids therapeutic use, Treatment Outcome, Antirheumatic Agents therapeutic use, Immunoglobulin G metabolism, Multiple Organ Failure diagnosis, Multiple Organ Failure drug therapy, Positron-Emission Tomography methods, Severity of Illness Index, Tomography, X-Ray Computed methods
- Abstract
Objective: To evaluate the usefulness of 2-[18F]-fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in IgG4-related disease (IgG4-RD) for the staging of the disease and the followup under treatment., Methods: All patients included in the French IgG4-RD registry who underwent ≥1 FDG-PET/CT scan were included in the study. Clinical, biologic, pathologic, radiologic, and FDG-PET/CT qualitative and quantitative findings were retrospectively collected and analyzed., Results: Twenty-one patients were included in the study and 46 FDG-PET/CT examinations were evaluated. At either diagnosis or relapse, all evaluated patients presented abnormal 18F-FDG uptake in typical IgG4-RD localizations. In most cases, FDG-PET/CT was more sensitive than conventional imaging to detect organ involvement, especially in arteries, salivary glands, and lymph nodes. In few cases (small-sized lesions and brain or kidney contiguous lesions), false-negative results were noted. Evaluation before and after treatment showed in most cases a good correlation of FDG-PET/CT results with treatment response and disease activity., Conclusion: This large retrospective study shows that FDG-PET/CT imaging is useful for the staging of IgG4-RD. Moreover, FDG-PET/CT is useful to assess the response to treatment during followup., (Copyright © 2014 by the American College of Rheumatology.)
- Published
- 2014
- Full Text
- View/download PDF
27. Babesia microti: an unusual travel-related disease.
- Author
-
Poisnel E, Ebbo M, Berda-Haddad Y, Faucher B, Bernit E, Carcy B, Piarroux R, Harlé JR, and Schleinitz N
- Subjects
- Aged, 80 and over, Babesia microti genetics, Babesiosis blood, Bone Marrow parasitology, France, Humans, Lymphohistiocytosis, Hemophagocytic, Male, Pancytopenia parasitology, United States ethnology, Babesia microti isolation & purification, Babesiosis diagnosis, Travel
- Abstract
Background: Human babesiosis is a rare tick-borne infectious disease. The clinical presentation ranges from an asymptomatic form to a life threatening infection with severe hemolysis. Human babesiosis due to Babesia microti is the most common and is endemic in North America., Case Presentation: We report a European patient with severe pancytopenia and reactive hemophagocytosis related to a Babesia microti infection. Babesia infection was acquired during a travel in the USA., Conclusion: Babesiosis should be considered in patients who traveled in endemic areas, especially North America for the most common agent Babesia microti.
- Published
- 2013
- Full Text
- View/download PDF
28. Pathologies Associated with Serum IgG4 Elevation.
- Author
-
Ebbo M, Grados A, Bernit E, Vély F, Boucraut J, Harlé JR, Daniel L, and Schleinitz N
- Abstract
Statement of Purpose. IgG4-related disease (IgG4-RD) is usually associated to an increase of serum IgG4 levels. However other conditions have also been associated to high serum IgG4 levels. Methods. All IgG subclasses analyses performed in our hospital over a one-year period were analyzed. When IgG4 level were over 1.35 g/L, the patient's clinical observation was analyzed and both final diagnosis and reason leading to IgG subclasses analysis were recorded. Only polyclonal increases of IgG4 were considered. Summary of the Results. On 646 IgG subclass analysis performed, 59 patients had serum IgG4 over 1.35 g/L. The final diagnosis associated to serum IgG4 increase was very variable. Most patients (25%) presented with repeated infections, 13.5% with autoimmune diseases, and 10% with IgG4-RD. Other patients presented with cancer, primary immune deficiencies, idiopathic interstitial lung disease, cystic fibrosis, histiocytosis, or systemic vasculitis and 13.5% presented with various pathologies or no diagnosis. Mean IgG4 levels and IgG4/IgG ratio were higher in IgG4-RD than in other pathologies associated to elevated IgG4 levels. Conclusions. Our study confirms that elevation of serum IgG4 is not specific to IgG4-RD. Before retaining IgG4-RD diagnosis in cases of serum IgG4 above 1.35 g/L, several other pathological conditions should be excluded.
- Published
- 2012
- Full Text
- View/download PDF
29. Clinical images: Bone sarcoidosis mimicking multiple metastases.
- Author
-
Mosnier E, Siles P, Ebbo M, Bernit E, Veit V, Tintignac A, Chagnaud C, Harlé JR, and Schleinitz N
- Subjects
- Adult, Bone Diseases diagnostic imaging, Female, Fluorodeoxyglucose F18, Humans, Low Back Pain diagnosis, Low Back Pain diagnostic imaging, Magnetic Resonance Imaging, Neoplasm Metastasis, Positron-Emission Tomography, Sarcoidosis diagnostic imaging, Technetium Tc 99m Pentetate, Tomography, X-Ray Computed, Bone Diseases pathology, Sarcoidosis pathology
- Published
- 2011
- Full Text
- View/download PDF
30. Two cases of intravascular lymphomatosis disclosing with hypopituitarism.
- Author
-
Schleinitz N, Bernit E, Mazodier K, Charbonnier A, Horchowski N, Andrac-Meyer L, Veit V, and Harlé JR
- Subjects
- Aged, Fatal Outcome, Female, Humans, Hypopituitarism complications, Lymphoma, Large B-Cell, Diffuse complications, Male, Vascular Neoplasms complications, Hypopituitarism diagnosis, Lymphoma, Large B-Cell, Diffuse diagnosis, Vascular Neoplasms diagnosis
- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.